Funding for this research was provided by:
AstraZeneca (ISSBRIL0174, D5130L00060)
Text and Data Mining valid from 2019-06-07
Received: 27 March 2019
Accepted: 31 May 2019
First Online: 7 June 2019
Ethics approval and consent to participant
: The Institutional Review Board at the Icahn School of Medicine at Mount Sinai in New York, NY approved this study.
: The manuscript was submitted to the sponsor for review before submission. The analysis of data and decision to publish these data were the sole decision of the investigators.
: Dr. Rosenson receives grant funding from Akcea, Amgen, AstraZeneca, Medicines Company and Regeneron. At the time of funding for this trial, he attended an Advisory Board for AstraZeneca. He receives consulting fees and honoraria from Amgen, C5, CVS Caremark and Kowa; royalties from UpToDate, Inc. and holds stock in MediMergent LLC. Dr. Chen and Mr. Najera report no relevant conflicts of interest. Dr. Krishnan receives consultanting fees Medtronic and Abbott. Dr. Lee and Mr. Cho receive consulting fees from Rheovector LLC.